Thermo Fisher Scientific (NYSE:TMO) EVP Frederick Lowery Sells 6,912 Shares of Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) EVP Frederick Lowery sold 6,912 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the completion of the sale, the executive vice president owned 14,367 shares of the company’s stock, valued at $8,360,731.98. This trade represents a 32.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $580.61 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The stock has a 50 day moving average price of $555.23 and a 200 day moving average price of $483.27. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The firm has a market capitalization of $218.14 billion, a P/E ratio of 33.54, a P/E/G ratio of 4.28 and a beta of 0.90.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has approved a share repurchase plan on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Institutional Trading of Thermo Fisher Scientific

Hedge funds and other institutional investors have recently modified their holdings of the business. Swiss Life Asset Management Ltd lifted its stake in Thermo Fisher Scientific by 4.7% during the third quarter. Swiss Life Asset Management Ltd now owns 45,080 shares of the medical research company’s stock worth $21,865,000 after purchasing an additional 2,007 shares in the last quarter. Groupama Asset Managment lifted its stake in Thermo Fisher Scientific by 58.9% in the third quarter. Groupama Asset Managment now owns 245,016 shares of the medical research company’s stock worth $118,838,000 after acquiring an additional 90,854 shares during the last quarter. Investment Research Partners LLC purchased a new position in Thermo Fisher Scientific in the third quarter valued at $311,000. Cambria Investment Management L.P. purchased a new stake in Thermo Fisher Scientific during the third quarter worth approximately $723,000. Finally, KERR FINANCIAL PLANNING Corp acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at $38,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMO has been the topic of a number of recent research reports. Argus increased their price objective on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday. Evercore ISI lifted their target price on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Wells Fargo & Company increased their price target on Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Finally, Barclays raised their price target on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $602.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.